Braftovi (encorafenib) — United Healthcare
Non-small cell lung cancer (NSCLC)
Initial criteria
- Diagnosis of non-small cell lung cancer (NSCLC)
- Presence of BRAF V600E mutation
- Disease is advanced OR recurrent OR metastatic
- Used in combination with Mektovi (binimetinib)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Braftovi therapy
- Used in combination with Mektovi (binimetinib)
Approval duration
12 months